Continuous Glucose Monitoring Metrics in the Assessment of Glycemia in Moderate-to-Advanced CKD in Diabetes
J Ling, Jack Kit‐Chung Ng, Eric S. H. Lau, Ronald C.W., Alice P.S. Kong, Andrea O. Y. Luk, Jeffrey SS Kwok, Cheuk‐Chun Szeto, Juliana C.N. Chan, Elaine Chow
Abstract
Introduction: Glycated hemoglobin A1c (HbA1c) has reduced reliability in advanced chronic kidney disease (CKD) owing to factors influencing red cell turnover. Recent guidelines support the use of continuous glucose monitoring (CGM) in glycemic assessment in these patients. We evaluated relationships between HbA1c and CGM metrics of average glycemia and glucose variability (GV) in moderate-to-advanced CKD. Methods: , and HbA1c 7.4 ± 0.8%). CGM metrics were estimated from blinded CGM (Medtronic Ipro2 with Enlite sensor) and compared with HbA1c in the same week. Results: = 0.03). Conclusion: . Time in hypoglycemia and glycemic variability are relevant glycemic targets for optimization not reflected by HbA1c.